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Background: Huntington disease (HD) is a genetic neurodegenerative disease leading to progressive motor,
cognitive, and behavioral decline. Subtle changes in these domains are detectable up to 15 years before a
definitive motor diagnosis is made. This period, called prodromal HD, provides an opportunity to examine lifestyle
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behaviors that may impact disease progression. Theoretical Framework: Physical activity relates to decreased
rates of brain atrophy and improved cognitive and day-to-day functioning in Alzheimer disease and healthy aging
populations. Previous research has yielded mixed results regarding the impact of physical activity on disease
progression in HD and paid little attention to the prodromal phase.
Methods: We conducted analyses of associations among current physical activity level, current and retrospective
rate of change for hippocampus and striatum volume, and cognitive, motor, and day-to-day functioning variables.
Participants were 48 gene-expanded cases with prodromal and early-diagnosed HD and 27 nongene-expanded
control participants. Participants wore Fitbit Ultra activity monitors for three days and completed the self-reported
International Physical Activity Questionnaire (IPAQ). Hippocampal and striatal white matter volumes were
measured using magnetic resonance imaging. Cognitive tests included the Stroop Color and Word Test, and the
Symbol Digit Modalities Test (SDMT). Motor function was assessed using the Unified Huntington’s Disease Rating
Scale total motor score (TMS). Day-to-day functioning was measured using the World Health Organization
Disability Assessment Schedule (WHODAS) version 2.0.
Results: Higher Fitbit activity scores were significantly related to better scores on the SDMT and WHODAS in case
participants but not in controls. Fitbit activity scores tracked better with TMS scores in the group as a whole,
though the association did not reach statistical significance in the case participants. Higher Fitbit activity scores
related to less day-to-day functioning decline in retrospective slope analyses. Fitbit activity scores did not differ
significantly between cases and controls.
Conclusions: This is the first known study examining the associations between activity level and imaging, motor,
cognitive, and day-to-day functioning outcomes in prodromal and early HD. Preliminary results suggest physical
activity positively correlates with improved cognitive and day-to-day functioning and possibly motor function in
individuals in the prodromal and early phase of the condition.
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Translational Science, grants from the Midwest Nursing Research Society, Sigma Theta Tau International Gamma
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Huntington disease (HD) is a rare neurological disease affecting 2.71 persons for every 100,000 persons
worldwide  that leads to progressive behavioral, cognitive, and motor decline. This autosomal dominant disorder is
caused by an expansion of the cytosine-adenine-guanine (CAG) repeat, which codes for the huntingtin protein .
The huntingtin protein is expressed ubiquitously and its function remains unknown, but is thought to play a role in
transcription regulation . Onset of clinical manifestations typically occurs between ages 30 and 50 . CAG repeat
length may explain approximately 50–70% of the variance in age of onset , with a recent study reporting a
correlation of 0.53 between CAG repeat length and age of diagnosis . Genetic modifiers are likely to contribute to
the wide variance in age of onset, and several potential genetic modifiers have been identified . Nevertheless,
the range of age of onset of motor features can vary widely at each CAG repeat length . The range with the
greatest variability in age of onset encompasses those with CAG repeats between 40 and 48, which accounts for
80% of the gene-expanded (i.e. CAG ≥36) population . Wexler and colleagues , controlling for CAG repeat
length along with shared and nonshared environments, found that in almost 4000 individuals, factors other than
genetic and heritable factors accounted for approximately 60% of the variance in age of onset. More recently, Lee
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and colleagues  found that 30% of variance in age of onset could be related to factors besides CAG repeat
length. Together, these data indicate a significant amount of variance related to disease onset may be associated
with other modifying factors.
Lifestyle factors, such as diet, substance use, cognitive reserve, and physical activity might be related to age of
HD onset . Pathological mechanisms in HD that could be impacted by lifestyle include oxidative stress and
inflammation, neuronal damage, altered DNA synthesis and repair, and epigenetic modifications .
Several randomized controlled trials have shown that physical exercise and physical therapy interventions improve
gait, balance, mood, and quality of life, as well as cognitive and day-to-day functioning in persons with diagnosed
HD . Data also indicate physical activity relates to improved cognitive performance, physical
functioning, mood, and quality of life in persons with dementia and mild cognitive impairment . Physical
activity protects against brain volume loss in healthy aging adults, and those at risk for, or diagnosed with,
neurodegenerative diseases, including those that affect areas of the brain affected by HD, such as the basal
ganglia and hippocampus . Putative protective effects of exercise on cognition include decreased
neuroinflammation , increased brain-derived neurotrophic factor (BDNF) activity , induction of neurogenesis ,
upregulation of heat shock proteins , and reduction of stress-induced hormone activity .
Despite data indicating positive effects of physical activity in diagnosed HD, the impact of physical activity on
prodromal HD remains unknown. Interventions to delay onset of HD should ideally begin before onset of motor
features , by which time the neurodegeneration is often extensive . In a retrospective study of 154 people with
diagnosed HD, researchers compared physical, intellectual, and passive lifestyles (based on leisure activities,
education, occupation, and domestic activity) and found that a passive lifestyle (i.e., low-intensity physical activity
and high sedentary activity) related to earlier onset and predicted age of onset independent of CAG repeat length,
although physical activity alone was not associated with age of onset . Data from mouse models are equivocal
with regard to whether physical activity can delay onset of HD manifestations, with some studies indicating wheel
running from an early age delays motor onset  while others have suggested the opposite . A single human
case study in prodromal HD indicated running may have accelerated HD progression in a marathon runner . The
limited data regarding the impact of physical exercise in prodromal HD reveals that understanding the effects of
differing levels of physical activity in people with the HD gene expansion is incomplete. Our study is the first that
examines the relationship between physical activity and brain volume, as well as cognitive, motor, and day-to-day
functioning in a prodromal and early HD sample.
Participants
The results in this article are from a subset of participants from the Neurobiological Predictors of Huntington’s
Disease (PREDICT-HD) study, a longitudinal 32-site observational study that has followed over 1300 gene-
expanded individuals and nongene-expanded control participants for over 12 years . All participants
traveling to the University of Iowa PREDICT-HD site between July 2012 and May 2013 were invited to participate
in the substudy. The study procedure was explained to all participants, and all participants gave written informed
consent. The study was done in accordance with the World Medical Association Declaration of Helsinki.
Participants included gene-expanded cases and nongene-expanded controls. Participants are considered gene-
expanded cases when they have CAG repeat lengths greater than 36. Controls have tested negative for the HD
gene expansion with CAG repeat lengths less than 35. All analyses compared outcomes of physical activity
between cases and controls.
Participants in PREDICT-HD have been tested for the HD gene expansion and know their gene status, but do not
exhibit motor features sufficient for an HD diagnosis upon enrollment into the study. However, some participants
meet the Unified Huntington’s Disease Rating Scale (UHDRS) criteria for motor diagnosis during the course study
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participation and are at that time considered to have early stage HD. There were four such participants in our
sample. Participants undergo a battery of cognitive, behavioral, and motor assessments, and MRI scans.
Participants were excluded from participating if they had any of the following: clinical evidence of an unstable
medical or psychiatric illness; alcohol or drug abuse within the past year; learning or developmental disability
requiring special education; or history of another neurological condition.
Activity monitoring
We used Fitbit Ultra activity monitors (Fitbit, Inc., San Francisco) and the self-report International Physical Activity
Questionnaire (IPAQ)  to collect physical activity data from participants. The Fitbit Ultra (herein referred to as
Fitbit) is a pedometer with a built-in accelerometer and altimeter that calculates steps taken, steps climbed, and
distance in miles. In a validation study, Fitbit was shown to underestimate energy expenditure by approximately
15%, but compliance was higher than with other devices . In order to facilitate compliance, the Fitbit was
preferred due to the possibility of mildly impaired cognitive function in prodromal and early HD . In a treadmill
validation study, the Fitbit was shown to be as reliable as ActiGraph for step counts, which was the primary metric
used for analysis . A systematic review evaluating the reliability and validity of common activity tracking devices
found that the Fitbit was highly correlated with laboratory-based studies while other studies found that at some
speeds, the Fitbit underreported steps . Given the exploratory nature of this study we proceeded with the Fitbit
trackers.
Participants were shown how to use the Fitbit and were instructed to wear it clipped on to their waist during three
self-defined “typical” days in a one-week period and to record dates of use on a record sheet. For example,
participants who worked 40 hours per week were instructed to wear the Fitbit for two work days and one weekend
day. If they participated in a regularly-scheduled physical activity (e.g. exercise class, recreation league sport, gym
workout), they were instructed to wear the Fitbit tracker on a day that included this activity. Participants were
instructed to put the Fitbit on immediately after waking up on selected days, and to remove it only when engaging
in physical activities involving water, when showering, and when going to sleep for the night. For physical activity
that involved water and required removing the Fitbit, participants were instructed to record their activity on the
record sheet. They were informed that they did not have to include showering as water activity. Participants were
instructed to mail back the Fitbit trackers and record sheets in the provided addressed-and-stamped envelopes.
Activity data were downloaded to the web interface provided by Fitbit, Inc. Fitbit activity scores were calculated by
combining the mean number of steps, miles, and stairs climbed over the three days to generate a total activity
score for each participant.
The 7-item IPAQ  is a self-report measure of physical activity that prompts participants to report the number of
days in the past week they engaged in sitting, walking, and moderate or vigorous physical activity, and to specify
the number of hours and minutes per day they spent in each activity. The IPAQ has demonstrated adequate
reliability and validity, including good test-retest reliability (Spearman’s ρ = 0.8 within 8 days), and fair to moderate
correlation (ρ = 0.30) between the IPAQ and accelerometer data . Although there are some reported concerns
about the reliability of the short form , we decided to use the IPAQ because it is a short measure that creates
minimal participant burden. While the Fitbit supplies data regarding the quantity of exercise a person participates
in on a daily basis, the IPAQ provides the self-reported level of vigor of physical activity levels. Participants
completed the IPAQ at home and returned it with the Fitbit trackers. We calculated IPAQ scores using the MET-
minutes (MET = median metabolic equivalent) method for continuous IPAQ scores . Essentially, each participant
indicates (for each category: walking, moderate, and vigorous activities) the average number of days during which
they engage in the specified activity, and how many hours each day they engage in said activity. These values are
then multiplied together by a corresponding weight based on estimated MET. It should be noted that sitting time is
not factored into the IPAQ variable analyzed below. The IPAQ and Fitbit participant scores were subsequently
matched to the entire PREDICT-HD dataset for analysis.
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Outcomes of interest included variables consistently shown to be associated with disease progression in
HD . The striatum and hippocampus imaging was conducted using various 1.5 and 3T scanners
based on study site. Volumes were analyzed using BRAINS image-processing software .
Cognitive tests included the Symbol Digit Modalities Test (SDMT)  and the Stroop Color and Word Test . The
SDMT is a timed test in which participants have 90 seconds to match digits with a provided symbol code. The
score reflects the number of correct responses, with higher scores indicating better cognitive function. The Stroop
Color and Word Test is made up of three timed tests in which participants (1) read color names printed in black ink;
(2) identify the color of ink patches on a sheet; and (3) identify the color of ink that color words are printed in,
including matching and non-matching word-color combinations. The final score refers to the number of correctly
stated items for each test in 45 seconds, with higher scores indicating better cognitive function.
The UHDRS is a clinician-rated exam that generates a total motor score (TMS) from a battery of motor
assessments (e.g., gait, involuntary movement, eye movement, dysarthria) . Scores can range from 0–124, with
higher scores indicating greater motor impairment. The 12-item World Health Organization Disability Assessment
Schedule (WHODAS) version 2.0 is a test of global day-to-day functioning  in which higher scores indicate worse
functioning. We chose to include the companion-rated measure in addition to the participant-rated measure due to
evidence of impaired reliability of self-report in the late prodromal period .
Analysis
All analyses were performed using the statistical software program R (version 3.1.2). The overall goal of the
analysis was to determine whether activity level is associated with progression in HD, and our exploratory aim was
to examine whether being physically active may have a protective effect with respect to HD-associated changes.
We calculated correlations between activity level (as measured by Fitbit and IPAQ) and cognitive, imaging, motor,
and functional variables to assess whether activity level correlates with variables collected in PREDICT-HD. We
also calculated correlations separately for gene-expanded and nongene-expanded individuals so as to assess
whether the correlation structure changed by gene status. Next, we fitted linear mixed models (LMMs) using all
available longitudinal data collected between 2002–2014 from PREDICT-HD to calculate progression indices for
individuals in the subset with physical activity data. Progression indices were defined in terms of fixed and random
slopes, so that each individual’s progression index is equal to his or her estimated annual change in the variable
under consideration. Random slopes were then correlated with activity data. Multiple testing was accounted for
using the false discovery rate (FDR).
Descriptive analyses
For this sub study, 87 PREDICT-HD participants at the University of Iowa were invited to participate. Of these 87,
one person declined to participate due to time concerns; one participant was ill the day of the study and withdrew;
one participant did not return physical activity data; nine participants had incomplete data (four participants did not
return IPAQ forms, four returned incomplete IPAQ forms, and six people returned Fitbits with no data on them);
and one participant for which activity data were collected was removed from the analysis because that participant’s
data were not contained in the latest data cut. Therefore, 75 participants with complete Fitbit and IPAQ data were
used for these analyses. Table 1 shows participant demographic data. Most of the gene-expanded participants
were in the prodromal stage. Four participants who completed the study had UHDRS diagnostic confidence level
scores of 4, indicating that they had symptoms consistent with HD motor diagnosis. The only significant difference
between cases and controls was mean CAG repeat length (F = 953.53, p < 0.001). For all other comparisons, p >
0.40.
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Results
Activity monitoring
Most participants returned the Fitbits along with the Fitbit activity record sheet and IPAQ questionnaires. Four
participants did not return Fitbit activity records with the Fitbits; however, we were able to use the data for analyses
by extrapolating their activity data and dates of activity from the Fitbit website. In these cases, the three days with
the most complete data were used. Seven participants recorded removing the Fitbits to shower or for water
activities (e.g. 5 hours at a water park, 1 hour water volleyball, 40 minutes water aerobics, 1 hour kayaking).
Several participants made notes on the record sheets to indicate atypical activity. These aberrations were either
more sedentary than usual (e.g., long car rides, watching a football game, heavy rain inhibiting daily walk) or more
active than usual (e.g., shoveling snow, long shopping trip, training for a marathon). Two participants recorded they
removed the Fitbit during intensive exercise (an intensive video exercise program, a marathon training run)
because the intensive exercise was not “typical” for them. We also encountered some technical issues with our
physical activity monitoring, with one of the Fitbits recording implausible data (e.g., a mismatch between steps
taken and miles tracked in a day or a mismatch in self-reported dates of activity and Fitbit recorded dates). The
tracker with step/miles mismatch was retired as soon as the problem occurred. One Fitbit tracker was lost, and
one was not returned.
Table 2 presents means, standard deviations, and ranges for variables in the analyses and shows that cases had
worse performance than controls on SDMT and TMS at the 0.05 level. At the 0.10 level, daily functioning for cases
was worse than controls, as rated by both participants and their companions. These findings indicate that even in
the prodromal phase, cases displayed subtle differences in cognitive, motor, and day-to-day functioning. Cases
self-reported higher physical activity levels on the IPAQ at the 0.10 level, although cases did not significantly differ
from controls in physical activity levels recorded by the Fitbits.
Table 1. Participant demographic variables
DCL = Diagnostic confidence level
Variable Case Control
n 48 27
Baseline mean age (SD) 45.68 (13.60) 47.99 (10.47)
Baseline mean age (SD) prodromal only 45.33 –
Gender: female n (%) 32 (66.66) 19 (70.37)
Gender: male n (%) 16 (33.33) 8 (29.63)
Mean CAG repeat length (SD) 41.81 (2.09) 20.63 (3.86)
Mean years of education (SD) 15.23 (2.20) 15.56 (2.22)
DCL = 4 4 N/A
Cross-sectional correlations
Table 3 contains cross-sectional correlations. For the combined sample, activity level (as measured by the Fitbit)
positively correlated with SDMT at the 0.10 level (r = 0.25, p = 0.056) and negatively correlated with the
participant-rated WHODAS (r = -0.36, p = 0.009). Fitbit activity level negatively correlated with TMS at the 0.10
level (r = -0.23, p = 0.080). Fitbit also positively correlated with IPAQ activity levels (r = 0.41, p = 0.002). For the
cases only sample, Fitbit activity level positively correlated with SDMT (r = 0.37, p = 0.034) and negatively
correlated with participant-rated functional level on the WHODAS (r = -0.37, p = 0.047). Fitbit activity level
positively correlated with IPAQ (r = 0.47, p = 0.009). No associations were significant in controls.
Table 2. Means, standard deviations, ranges for all variables
Note: ~ corresponds to 0.05 < p < 0.10, + corresponds to 0.01 < p < 0.05SDMT = Symbol Digit Modalities Test; WHODAS = World
Health Organization Disability Assessment Schedule 2.0; (p) = participant; (c) = companion; TMS = total motor score from the
United Huntington’s Disease Rating Scale; IPAQ = International Physical Activity Questionnaire.
Variable Case mean (SD)[range] n Control mean (SD)[range] n
SDMT 50.80 (11.77)+ [25–76] 45 58.11 (8.88)[43–78] 27
WHODAS (p) 16.67 (6.36)~ [12–35] 40 13.48 (1.97)[12–19] 24
WHODAS (c) 15.97 (4.39)~[12–26] 39 13.73 (2.61)[12–21] 18
TMS 8.23 (11.65)+[0–45] 47 2.15 (3.17)[0–12] 27
IPAQ 3728 (3696)~[0–17788] 39 2051 (2131)[0–8088] 25
Fitbit 6781 (3587)[1414–16091] 48 7137 (2515)[3455–15054] 26
Scatterplots of Fitbit activity level with PREDICT-HD variables
Figure 1 depicts scatterplots of all cross-sectional pairs of Fitbit activity levels with commonly analyzed PREDICT-
HD variables, such as the Stroop Color and Word Test, SDMT, WHODAS, TMS, and hippocampal and striatal
brain volumes. These plots suggest activity levels, as measured with the Fitbit, may be associated with important
outcomes in HD, including cognition (SDMT) and daily functioning (WHODAS).
Table 3. Cross-sectional correlation table
Note: ~ corresponds to 0.05 < p < 0.10, + corresponds to 0.01 < p < 0.05, ++ corresponds to 0.001 < p < 0.01. SDMT = Symbol
Digit Modalities Test; WHODAS = World Health Organization Disability Assessment Schedule 2.0; (p) = participant; (c) =
companion; TMS = total motor score from the United Huntington’s Disease Rating Scale; IPAQ = International Physical Activity
Questionnaire.
Combined sample Cases Controls
Outcome Variable IPAQ Fitbit IPAQ Fitbit IPAQ Fitbit
Stroop Word -0.17 0.07 -0.11 0.05 -0.20 0.10
Stroop Color -0.13 0.13 -0.05 0.14 -0.16 0.03
Stroop Interference -0.11 0.10 -0.13 0.11 0.08 0.04
SDMT -0.04 0.25~ -0.02 0.37+ 0.12 -0.13
WHODAS (p) -0.01 -0.36++ -0.08 -0.37+ -0.09 -0.35
WHODAS (c) 0.10 -0.20 0.03 -0.21 0.12 -0.15
TMS 0.18 -0.23~ 0.10 -0.24 0.34 -0.15
Hippocampal volume -0.20 -0.07 -0.18 -0.17 0.08 0.03
Striatal volume -0.10 0.06 -0.03 -0.05 0.27 0.18
IPAQ – 0.41++ – 0.47++ – 0.35
Fitbit 0.41++ – 0.47++ – 0.35~ –
Fig. 1: Scatterplots of correlations between Fitbit activity scores and outcome variables.
Notes: SDMT = Symbol Digit Modalities Test (higher scores indicate higher cognitive function); WHODASp = World
Health Organization Disability Assessment Schedule 2.0 participant version (lower scores indicate higher day-to-day
function).
Random slope correlations
A correlation matrix for the random slopes calculated from a linear mixed-effects regression analysis and activity
level data is presented in Table 4. WHODAS participant slopes were negatively correlated with Fitbit activity level
(r = -0.28, p = 0.039), and WHODAS (companion) slopes were negatively correlated with Fitbit activity level (r =
-0.26, p = 0.065) at the 0.10 level.
In this study, we examined associations between physical activity level and a variety of outcome variables with
demonstrated sensitivity to changes in prodromal HD . We collected physical activity data at participants’ most
recent visit and compared this to their cognitive, behavioral, motor, functional, and imaging variables at the same
visit, and to the rate of changes in the same variables from previous annual research visits. HD gene-expanded
participants self-reported more physical activity on the IPAQ than nongene-expanded controls, but did not
significantly differ in physical activity captured by Fitbit activity monitors. We used the short form of the IPAQ to
limit participant burden. However, the short form of the IPAQ has questionable reliability , which might account for
the low correlations with the Fitbit scores in our study. The low correlations of the IPAQ to Fitbit scores may also be
due to the fact that this is a cognitively impaired population, so perhaps self-reported exercise measures are not
appropriate. Due to the limitations of the IPAQ, we focused on the associations between the more objectively
recorded Fitbit physical activity measures rather than the self-reported IPAQ.
Given that Fitbit physical activity levels were similar between cases and controls, differences in outcome measures
between cases and controls are less likely to be due to differences in level of physical activity between the groups.
That is, any benefit seen is likely related to the level of physical activity since we only expect to see a cognitive or
functional decline in the gene-expanded cases. In this study, higher Fitbit activity scores correlated with better
cognitive functioning on the SDMT at the most recent visit for cases but not for controls. Since activity levels were
similar between cases and controls this finding suggests that physical activity might provide cognitive benefits for
people with the HD gene expansion.
The positive association between physical activity and the SDMT is a provocative preliminary result because the
SDMT provides greater sensitivity to change in cognitive function in prodromal HD than the Stroop tests . This
enhanced effect size permitted us to identify changes in SDMT that would likely not be possible with Stroop tests.
Our finding supports those from Piira and colleagues , who found improvement on the SDMT, but no significant
improvement on the Stroop tests, in a similarly-sized sample of early- and mid-stage HD participants following an
intensive physical rehabilitation program.
We did not find evidence that physical activity is related to hippocampal or striatal volume, despite studies
indicating that physical activity can maintain the volumes of these structures in aging adults and adults at risk for
Alzheimer disease (AD) . However, we did not collect longitudinal physical activity data, which is a limitation
of this study and a necessity for future studies looking at brain volume changes over time. Physical activity may
also produce cognitive benefits by promoting compensatory neuronal pathways via increased connectivity, which
would require use of other imaging techniques, such as functional connectivity with resting state MRI or white
matter tract integrity with diffusion tensor imaging.
In the rate-of-change analyses, we analyzed the correlations between physical activity, as measured at the most
recent research visit, and rate of change over time. We found positive correlations between physical activity level
and performance on the WHODAS, a measure of day-to-day functioning. This finding suggests physical activity
Table 4. Correlation matrices of random slopes and exercise indices
Note: ~ corresponds to 0.05 < p < 0.10, + corresponds to 0.01 < p < 0.05. SDMT = Symbol Digit Modalities Test; WHODAS =
World Health Organization Disability Assessment Schedule; (p) = participant; (c) = companion; TMS = total motor score from the
United Huntington’s Disease Rating Scale; IPAQ = International Physical Activity Questionnaire.
Stroop
Interference
SDMT WHODAS
(p)
WHODAS
(c)
TMS Hippocampal
Volume
Striatal
Volume
IPAQ -0.12 -0.10 -0.15 0.08 0.20 -0.06 -0.20
Fitbit 0.16 0.08 -0.28+ -0.26~ -0.20 -0.04 0.04
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might help preserve physical functioning and independence. However, we cannot discount the possibility that
people who have better day-to-day functioning feel able to be more physically active. The relationship between
higher activity levels and WHODAS performance is also a promising indicator that, if indeed physical activity can
improve functioning and independence, health-related quality of life would also improve .
Our study had a high recruitment-and-retention rate; only one PREDICT-HD participant declined to participate in
the add-on study due to concerns about time commitment. In addition, 75/83 (90%) of the participants we enrolled
completed the activity portion of the study, in line with another study involving an exercise intervention for people
with diagnosed HD that had a retention rate of 81% . This indicates that physical activity intervention programs
are feasible, even in patients with early diagnosed HD.
This study had some limitations. We did not measure physical activity longitudinally. Instead, we made the
assumption that one-time physical activity data for each participant would reflect their recent exercise history.
However, collecting longitudinal physical activity data would be preferable. We have a small sample size for this
study. More data are needed with larger samples to determine the effects of physical activity on cognitive function.
We also encountered some technical issues with the Fitbit, as noted above. More recent models of the Fitbit are
now available and could provide more accurate data. It is also possible that people did not accurately report
compliance with wearing the Fitbits. However, the number of people recording deviations in following the protocol
(temporary removal) provides some indication that at least those participants were conscientious about using the
Fitbit as instructed. There were other instances where a Fitbit was returned without self-reported date sheets. In
these situations we extrapolated accurate data by using dates with physical activity recorded in the Fitbit database.
There is also a limitation of the reliability of the accelerometer accuracy in a population that could have chorea
movements. It is not known how this Fitbit device would calculate these disease-associated movements.
Also, we recruited participants year round. It is possible that participants recruited in the winter months had lower
activity levels than others given that it is more difficult to participate in outdoor activities in cold weather. We also
did not account for water activities that were not recorded by the Fitbit. In future studies, water activity should be
accounted for, and all activity scores should be converted to one metric, such as METs. Despite the limitations in
using the Fitbit and the IPAQ, our study demonstrates it is feasible to collect physical activity data from participants
with prodromal and early stage HD. Future studies might also benefit from ensuring that a companion is involved,
which might help ensure accurate completion of forms.
The prodromal participants in our study may be older than other prodromal individuals in the population. HD
typically manifests in the late thirties or early forties. Our mean age of enrollment of 45.3 years for prodromal
participants is comparable with manifest participants from other studies. If health behaviors impact age of onset,
this age difference might reflect lifestyle factors that delay onset. For example, our gene-expanded participants
had a higher average education level (15.1 years) than the average for United States residents. More education
has been associated with better cognitive function in people with HD , ostensibly by contributing to cognitive
reserve, which is also associated with a reduced risk of AD .
Interventions that could delay the onset of an HD motor diagnosis, particularly at a time when people are at their
peak earning potential and raising families, may improve functioning and health-related quality of life. Interventions
should begin prior to motor diagnosis because there is some evidence that much of the damage the disease
causes is done by the time of diagnosis . More specific recommendations require prospective, randomized
controlled trials of physical activity interventions. There is evidence that metabolic and physiological responses to
exercise are altered in HD  and that intensive exercise might damage muscle tissue , requiring a careful
determination of the proper dose of exercise to forestall HD progression. In one study involving aging adults at risk
for mild cognitive impairment (MCI), moderate exercise was more strongly related to reduced odds for developing
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MCI than light or vigorous exercise . Perhaps this is a recommendation that could be explored for relevance for
HD.
Physical activity is an easy-to-implement, low-cost intervention that may help delay cognitive decline in gene-
expanded persons, and also may have health benefits for at-risk HD family members who have not yet been
tested or who do not want to be tested. Physical activity is a health behavior that can be started at a very young
age. Children who are at risk can participate in family physical activities. Those habits started at a young age can
continue throughout the child’s life, offering benefits for overall health, and could have a potential protective effect
with respect to early cognitive decline associated with HD.
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